Artwork
iconShare
 
Manage episode 505502759 series 3677839
Content provided by Tyler Menichiello. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Tyler Menichiello or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Nicole Paulk, Ph.D., CEO and founder of Siren Biotechnology, a company developing a universal AAV immuno-gene therapy for cancer. They discuss the company’s decision to switch from plasmids to producer cell lines (PCLs) in production, the current funding environment for cell and gene therapies (CGTs), how companies are innovating and doing more with less, and the unconventional head-to-head competition that determined which CDMO won Siren’s business.

Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/
Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/
Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions

  continue reading

9 episodes